Rogers Lisa R, Ostrom Quinn T, Schroer Julia, Vengoechea Jaime, Li Li, Gerson Stanton, Nock Charles J, Machtay Mitchell, Selman Warren, Lo Simon, Sloan Andrew E, Barnholtz-Sloan Jill S
Neurological Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Department of Medicine, Section of Epidemiology and Population Health, Baylor College of Medicine, Houston, Texas.
Neurooncol Pract. 2020 Mar 31;7(5):541-548. doi: 10.1093/nop/npaa011. eCollection 2020 Oct.
Metabolic syndrome is identified as a risk factor for the development of several systemic cancers, but its frequency among patients with glioblastoma and its association with clinical outcomes have yet to be determined. The aim of this study was to investigate metabolic syndrome as a risk factor for and affecting survival in glioblastoma patients.
A retrospective cohort study, consisting of patients with diagnoses at a single institution between 2007 and 2013, was conducted. Clinical records were reviewed, and clinical and laboratory data pertaining to 5 metabolic criteria were extrapolated. Overall survival was determined by time from initial surgical diagnosis to date of death or last follow-up.
The frequency of metabolic syndrome among patients diagnosed with glioblastoma was slightly greater than the frequency of metabolic syndrome among the general population. Within a subset of patients ( = 91) receiving the full schedule of concurrent radiation and temozolomide and adjuvant temozolomide, median overall survival was significantly shorter for patients with metabolic syndrome compared with those without. In addition, the presence of all 5 elements of the metabolic syndrome resulted in significantly decreased median survival in these patients.
We identified the metabolic syndrome at a slightly higher frequency in patients with diagnosed glioblastoma compared with the general population. In addition, metabolic syndrome with each of its individual components is associated with an overall worse prognosis in patients receiving the standard schedule of radiation and temozolomide after adjustment for age.
代谢综合征被认为是多种全身性癌症发生的危险因素，但其在胶质母细胞瘤患者中的发生率及其与临床结局的关联尚未确定。本研究的目的是调查代谢综合征作为胶质母细胞瘤患者的危险因素及其对生存的影响。
进行了一项回顾性队列研究，研究对象为2007年至2013年在单一机构确诊的患者。回顾临床记录，并推断出与5项代谢标准相关的临床和实验室数据。总生存期通过从初次手术诊断到死亡日期或最后一次随访的时间来确定。
诊断为胶质母细胞瘤的患者中代谢综合征的发生率略高于普通人群中代谢综合征的发生率。在接受同步放化疗和辅助替莫唑胺全疗程治疗的患者亚组（n = 91）中，代谢综合征患者的中位总生存期明显短于无代谢综合征的患者。此外，代谢综合征所有5个要素的存在导致这些患者的中位生存期显著缩短。
我们发现，与普通人群相比，诊断为胶质母细胞瘤的患者中代谢综合征的发生率略高。此外，在调整年龄后，代谢综合征及其各个组成部分与接受标准放化疗方案的患者总体预后较差有关。
